Jeffrey F. Ohren
Vice President of Biology @Type6 Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Vice President of Biology @Type6 Therapeutics
CA, US
Type6 Therapeutics, Inc. has exited stealth mode! We are excited to announce that our novel CDK2 kinase inhibitor program has exceeded expectations at the pre-clinical stage. Stay tuned for more details!
EDUCATION
Northern Kentucky University
B.A., Chemistry, Biochemistry track
The University of Toledo
M.Sc., Chemistry, X-ray crystallography
University of Toledo
Ph.D., Chemistry, Protein Chemistry, X-ray crystallography
SKILLS
ABOUT JEFFREY F. OHREN
Delivering innovative solutions to complex problems at the interface of chemistry, biology, computational sciences and medicine- Leader of the structural biology team that first structurally characterized the mechanism of action for the marketed MEK inhibitor, Mekinist™ (trametinib)- Nearly thirty peer-reviewed publications demonstrates a track record of success in protein chemistry, structural biology and bio-analytical chemistry. Significant expertise in kinase structure-based drug design- Excellence at the bench and computational desktop, skilled at project leadership and team engagement in a matrix environment. Highly effective communicator.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.